Alternatives to Traditional Unit Operations Are Now Available to Alleviate Very Real Logjams Due to the complexity of therapeutic protein purification, downstream bioprocess bottlenecks can arise from ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

The cell and gene therapy industry will greatly benefit from access to robust, scalable, end-to-end solutions for the production and characterization of native and engineered exosome therapeutics.” — ...

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

Standards organization says R2v3 certification entails accurately portraying operations of facilities receiving components and materials. SERI says qualifications for a non-R2v3 downstream vendor are ...

Real-time and in-line accurate measuring of protein (monoclonal antibody, or mAb) concentration has been shown across a wide dynamic range (0–135 g/L) through the ...

LONDON--(BUSINESS WIRE)--Quantzig is one of the world’s leading analytics solutions providers, committed to offering cutting-edge analytics solutions to help organizations institutionalize data-driven ...

“However, the downstream equipment presents a much bigger challenge due to the significant investment required to add capacity to the proofer and oven, if possible at all,” he pointed out. “Another ...